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Abstract
Background and Objective Co-Crystal of Tramadol–Celecoxib (CTC), in development for the treatment of moderate to 
severe acute pain, is a first-in-class co-crystal containing a 1:1 molecular ratio of two active pharmaceutical ingredients; rac-
tramadol·HCl and celecoxib. This randomised, open-label, crossover study compared the bioavailability of both components 
after CTC administration under fed and fasting conditions.
Methods Healthy adults received single doses of 200 mg CTC under both fed and fasting conditions (separated by a 7-day 
washout). Each dose of CTC was administered orally as two 100 mg tablets, each containing 44 mg tramadol·HCl and 
56 mg celecoxib. In the fed condition, a high-fat, high-calorie meal [in line with recommendations by the US Food and 
Drug Administration (FDA)] was served 30 min before CTC administration. Tramadol, O-desmethyltramadol and celecoxib 
plasma concentrations were measured pre- and post-dose up to 48 h. Pharmacokinetic parameters were calculated using 
non-compartmental analysis. Safety was also assessed.
Results Thirty-six subjects (18 female/18 male) received one or both doses of CTC; 33 provided evaluable pharmacokinetic 
data under fed and fasting conditions. For tramadol and O-desmethyltramadol, fed-to-fasting ratios of geometric least-squares 
means and corresponding 90% confidence interval (CI) values for maximum plasma concentration (Cmax) and extrapolated 
area under the plasma concentration–time curve to infinity (AUC ∞) were within the pre-defined range for comparative bio-
availability (80–125%). For celecoxib, Cmax and AUC ∞ fed-to-fasting ratios (90% CIs) were outside this range, at 130.91% 
(116.98–146.49) and 129.34% (121.78–137.38), respectively. The safety profile of CTC was similar in fed and fasting 
conditions.
Conclusions As reported for standard-formulation celecoxib, food increased the bioavailability of celecoxib from single-dose 
CTC. Food had no effect on tramadol or O-desmethyltramadol bioavailability.
Clinical trial registration number 152052 (registered with the Therapeutic Products Directorate of Health Canada)
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Key Points 
Co-Crystal of Tramadol–Celecoxib (CTC), a first-in-
class active pharmaceutical ingredient (API–API) co-
crystal of rac-tramadol·HCl and celecoxib, is in develop-
ment for the treatment of moderate to severe acute pain.
Food effects are reported for standard drug formula-
tions of celecoxib; the present study investigated the 
effects of food on the oral bioavailability of tramadol and 
celecoxib after CTC (200 mg) administration.
As for standard drug formulations of the individual 
reference products, food increased the bioavailability of 
celecoxib but not that of tramadol; therefore, as for these 
reference products, specific dosing recommendations 
relating to meal times are not anticipated to be required 
for CTC.
1 Introduction
Pharmaceutical co-crystals, which usually consist of an 
active pharmaceutical ingredient (API) and one or more co-
formers, provide a means to modify the physicochemical, 
pharmacokinetic—and therefore potentially the clinical—
properties of the constituent API [1–3]. Co-crystals contain-
ing more than one API (multidrug or ‘API–API’ co-crys-
tals) may also provide a novel method of delivering a drug 
treatment with multiple mechanisms of action. Co-Crystal 
of Tramadol–Celecoxib (CTC) is a first-in-class API–API 
co-crystal in development for the treatment of moderate to 
severe acute pain.
CTC contains rac-tramadol·hydrochloride (HCl) and 
celecoxib in a 1:1 molecular ratio, with 100 mg CTC com-
prising 44 mg tramadol.HCl and 56 mg celecoxib. This 
co-crystal targets pain through four complementary mech-
anisms of action: cyclooxygenase-2 inhibition, µ-opioid 
receptor agonism, noradrenaline reuptake inhibition and 
serotonin reuptake inhibition [4]. CTC may therefore 
provide multimodal analgesia, a treatment approach rec-
ommended in acute pain [5, 6], the optimal management 
of which continues to be hampered by lack of treatment 
efficacy [5, 7] and issues regarding side effects [8]. Ana-
lytical studies have confirmed that the physicochemical 
properties of both tramadol and celecoxib are modified 
by co-crystallisation [4]. For example, the intrinsic dis-
solution rate of tramadol is slower, and that of celecoxib 
faster, compared with individual reference products [4]. 
Synergistic antinociceptive effects have been observed in 
preclinical in vivo studies, without potentiation of adverse 
effects [9]. The analgesic effects of CTC (100, 150 and 
200 mg) have also been demonstrated in a Phase 2 clini-
cal study in patients with acute moderate to severe pain 
following extraction of two or more impacted third molars 
requiring bone removal [10].
The clinical pharmacokinetics of CTC were first char-
acterised in two Phase 1 studies conducted in healthy male 
and female subjects; one assessing a single dose of CTC 
[11] and one assessing multiple doses [12]. In both stud-
ies, differences in the pharmacokinetics of tramadol and 
celecoxib were seen after administration of CTC com-
pared with after administration of the individual refer-
ence products (immediate-release tramadol or celecoxib) 
alone or in free combination. In the case of tramadol, a 
lower maximum observed plasma concentration (Cmax), 
slightly prolonged time to Cmax (Tmax) and similar area 
under the plasma concentration–time curve (AUC) were 
observed with CTC. In the case of celecoxib pharmacoki-
netics after CTC administration, celecoxib had a lower 
Cmax compared with celecoxib alone, and a faster Tmax 
compared with celecoxib alone or in free combination with 
tramadol [11, 12].
The Phase 1 studies described above were conducted in 
fasting conditions. The bioavailability of tramadol from its 
standard drug formulation is not affected by food intake [13]. 
However, a high-fat meal slows absorption of celecoxib from 
its standard formulation by around 1 h, and increases the 
Cmax and AUC [14, 15]. The primary objective of the present 
study was therefore to assess the bioavailability of tramadol 
and celecoxib after a single dose of CTC, when administered 
in the fed or fasting state. The secondary objective was to 
evaluate the safety of CTC following single-dose administra-
tion in the fed or fasting state.
2  Methods
2.1  Study Subjects
Subjects were male or female volunteers aged 18–55 years, 
with a body mass index ≥ 18.5 and < 29 kg/m2. Subjects 
were required to be in good health, with no clinically sig-
nificant findings as determined by physical examination, 
electrocardiogram (ECG), clinical laboratory evaluations 
(haematology, biochemistry and urinalysis) and review of 
the subject’s medical history. Subjects were also required to 
be non-smokers (or ex-smokers for at least 6 months). Key 
exclusion criteria included pregnancy or lactation; a history 
of significant hypersensitivity to tramadol, celecoxib, sul-
phonamides, opioid analgesics or any related products; or 
a history of severe hypersensitivity reactions to any drugs. 
Full inclusion and exclusion criteria are included in Online 
Resource 1.
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2.2  Study Design and Treatments
This study was a single-centre, randomised, single-dose, 
open-label, two-period, two-sequence, crossover, food effect 
study. The study was conducted by a clinical research organi-
sation (CRO; Algorithme Pharma) at a single site in Quebec, 
Canada and registered with the Therapeutic Products Direc-
torate of Health Canada (152052). The study protocol was 
approved by an independent ethics committee and the study 
was performed in compliance with Good Clinical Practice. 
Institutional review board guidelines on the treatment of 
human subjects were followed, meeting the requirements of 
the Declaration of Helsinki. All subjects voluntarily enrolled 
in the study and gave written informed consent.
Each subject received a single oral dose of 200 mg 
CTC, once under fed conditions and once under fasting 
conditions. This dose had previously been evaluated in two 
earlier Phase 1 studies [11, 12] and was also efficacious 
and well tolerated in a Phase 2 study in which doses of 50, 
100, 150 and 200 mg CTC were administered [10]. CTC 
(Esteve Pharmaceuticals, S.A., Spain) was provided as 
two 100 mg tablets, each containing 44 mg tramadol·HCl 
and 56 mg celecoxib. Subjects were randomly assigned 
to one of two sequences—fed–fasting or fasting–fed—via 
a list generated using a computer application developed 
by Algorithme Pharma. Dosing was separated by a 7-day 
washout period (Fig. 1). All subjects underwent a super-
vised overnight fast (≥ 10 h) before each CTC administra-
tion and fasted for at least 4 h following administration, 
after which a standardised meal was served. In the fed 
condition, the overnight fast was followed by consump-
tion of a standardised high-fat, high-calorie meal [in line 
with the US Food and Drug Administration (FDA) rec-
ommendations] [16] 30 min before CTC administration. 
During the study, restrictions were applied to prescription 
medications; over-the-counter products; alcohol; xanthine, 
grapefruit- and pomelo-containing food or beverages; and 
strenuous activity. Water was permitted ad libitum until 
1-h pre-CTC administration and again from 1-h post-
administration. CTC was administered with approximately 
240 mL water.
2.3  Pharmacokinetic Sampling and Analytical 
Methods
During each treatment period, blood samples (4 mL each) 
were collected for pharmacokinetic analysis before CTC 
administration (at 0 h) and at 0.5, 1, 1.5, 1.75, 2, 2.33, 2.67, 
3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 36 and 48 h post-admin-
istration. Additional samples were taken at 3.33, 3.67, 4.5 
and 5.5 h post-administration in the fed state and at 0.75 
and 1.25 h post-administration in the fasting state. Samples 
were collected in pre-cooled  K2-EDTA-containing tubes 
and centrifuged (at 4 °C and 1500×g for 10 min) as soon 
as possible after collection. Plasma was then separated, 
frozen at a nominal temperature of–20 °C and transported 
on dry ice to the laboratory for assay.
Fig. 1  Study design and subject 
disposition. *The terminal 
phases of celecoxib could not be 
adequately estimated follow-
ing CTC administration in the 
fasting state in three subjects. 
AUC ∞ extrapolated area under 
the plasma concentration–time 
curve to infinity, CTC Co-Crys-





▪  200 mg CTC in ‘fed’ state, then 200 mg CTC
    in ‘fasting’ state
▪  7-day washout period between treatments
Fasting–fed (n=18)
▪  200 mg CTC in ‘fasting’ state, then 200 mg
   CTC in ‘fed’ state
▪  7-day washout period between treatments
Withdrawn due to emesis after dosing of 
period 2 that could have affected the PK 
profile (n=2)
Withdrew consent prior to dosing of period 2
for personal reasons (unrelated to clinical
events) (n=1)
Analysed:
Descriptive and statistical PK analysis: n=33
(n=30 for celecoxib AUC∞ and T½el)*
Safety analysis: n=36
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2.4  Bioanalytical Assay
Plasma concentrations of tramadol, O-desmethyltramadol 
(tramadol’s main metabolite) and celecoxib were meas-
ured using validated high-performance liquid chromatog-
raphy with tandem mass spectrometry methods.
Samples (0.05  mL) were extracted by solid-phase 
extraction in Oasis MCX 96-well plates (10 mg sorbent, 
30 μm particle size; Waters Corporation). After clean-up, 
the eluate obtained with methanol was used for analysis 
of celecoxib and the posterior eluate obtained with 5% 
 NH4OH in methanol was used for analysis of tramadol 
and O-desmethyltramadol. Celecoxib was separated on 
an XBridge C18 column (3.5 μm 50 × 2.1 mm; Waters 
Corporation) and tramadol and O-desmethyltramadol 
were separated on an Acquity UPLC BEH Shield RP18 
column (1.7 μm 2.1 × 50 mm; Waters Corporation) using 
different gradients of methanol and 0.1% formic acid in 
water. Detection for celecoxib was performed via tan-
dem mass spectrometry on an API 4000 triple quadru-
pole mass spectrometer (Sciex, Ontario, Canada) using 
negative electrospray ionisation. For tramadol and 
O-desmethyltramadol, a Xevo TQ MS triple quadrupole 
mass spectrometer using positive electrospray ionisation 
(Waters Corporation) was used. Propranolol and E-6087, 
a cyclooxygenase-2 inhibitor, were used as internal 
standards for tramadol (and O-desmethyltramadol) and 
celecoxib, respectively.
During validation of these methods, parameters eval-
uated were linearity and range; selectivity; specificity; 
intra- and inter-run precision and accuracy; limit of quan-
tification; dilution integrity; carry over; recovery; matrix 
effect; and stability in the autosampler at room tempera-
ture, after freeze-thaw cycles and over the long term. The 
lower and upper limits of quantification were 4.00 and 
640.00, 1.00 and 160.00, and 2.50 and 1000.00 ng/mL, 
for tramadol, O-desmethyltramadol and celecoxib, respec-
tively. Assay inter-run precision (coefficient of variation; 
CV) and accuracy (nominal values) for the limit of quan-
tification were 8.3 and 102.5%, respectively for trama-
dol, 10.1 and 105.2% for O-desmethyltramadol and 10.5 
and 107.8% for celecoxib. Assay specificity was assessed 
using six independent matrix sources, verified for the 
absence of interference, and compared with the respective 
limits of quantification at the retention times and mass 
transitions of analytes and internal standards. The abso-
lute recovery ranged from 70.2 to 73.3% for tramadol, 
76.3–80.5% for O-desmethyltramadol and 81.6–86.2% for 
celecoxib. Samples were stored for a maximum of 63 days 
(the long-term stability of frozen samples was confirmed 
up to 154 days).
2.5  Safety Assessments
Safety was monitored throughout the study via the assess-
ment of adverse events (AEs), classified using the Medical 
Dictionary for Regulatory Activities (MedDRA), version 
13.1. Assessment of vital signs and standard clinical labo-
ratory parameters (haematology, biochemistry and urinaly-
sis), ECGs and a physical examination were conducted at 
screening and at the end of the study, and vital signs were 
also measured prior to each CTC administration.
2.6  Data Analyses and Statistics
Findings from previous studies conducted with celecoxib 
at the CRO suggested that the intra-subject CV following 
a single dose of celecoxib was approximately 28% for Cmax 
and around 12% for cumulative AUC from time zero to time 
of last observed quantifiable plasma concentration (AUC t). 
Ratios of geometric least-squares (LS) means were expected 
to fall between 95 and 105%. Therefore, it was estimated 
that 32 subjects would be required to provide an adequate 
assessment of the effect of food on celecoxib bioavailabil-
ity following CTC administration. Thirty-six subjects were 
recruited to allow for the possibility of drop-outs and vari-
ations around the estimated intra-subject CV. As celecoxib 
was known to be subject to higher intra-subject variabil-
ity than tramadol or O-desmethyltramadol, these calcula-
tions also provided an adequate estimation of the sample 
size required to assess the bioavailability of these latter two 
analytes.
The main pharmacokinetic parameters evaluated for all 
three analytes were Cmax; Tmax; AUC t; extrapolated AUC to 
infinity (AUC ∞); and elimination half-life (T½el). Descrip-
tive pharmacokinetic analyses were conducted using a non-
compartmental approach and a log-linear terminal phase was 
assumed. The trapezoidal rule was used for AUC estimates 
and the terminal phase was estimated by maximizing the 
coefficient of determination calculated using a log-linear 
regression model. The natural logarithmic (ln) transforma-
tions of Cmax, AUC t and AUC ∞ were used for statistical 
pharmacokinetic analyses. All pharmacokinetic parameters 
except Tmax were analysed using an analysis of variance 
(ANOVA; in line with regulatory requirements [17]), with 
fixed factors of subject (nested within sequence), treatment, 
treatment period and sequence. Tmax was analysed via a 
non-parametric approach, using Wilcoxon’s rank sum test 
(Mann–Whitney U test). The comparative bioavailability of 
tramadol, M1 and celecoxib between fed and fasting states 
was assessed using a confidence interval (CI) approach. Fed-
to-fasting ratios of geometric LS means and corresponding 
90% CIs were calculated for Cmax, AUC t and AUC ∞. For 
each analyte, bioavailability was considered comparable if 
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fed-to-fasting ratios and corresponding 90% CIs of these 
parameters were within the pre-defined range of 80–125%.
Subjects who provided measurable data in both treatment 
conditions were included in the descriptive and statistical 
pharmacokinetic analyses. All subjects who received at least 
one dose of CTC were included in the safety analyses.
3  Results
3.1  Subjects
The study was initiated on 25 January 2012 and completed 
on 8 February 2012. Thirty-six subjects (18 male and 18 
female) were enrolled and received at least one dose of CTC; 
35 of these subjects were administered single-dose CTC 
in both fed and fasting conditions. Subject demographics 
and characteristics are summarised in Table 1. Thirty-four 
subjects (94%) were white; mean age was 35 years. One 
subject withdrew consent prior to dosing in the fasting state 
for personal reasons that were unrelated to any clinical event. 
Two subjects were withdrawn after dosing in the fed state 
due to emesis that could have affected pharmacokinetic 
findings. All subjects were included in the safety analysis. 
Thirty-three subjects provided evaluable pharmacokinetic 
data in both fed and fasting conditions and were therefore 
included in both descriptive and statistical pharmacokinetic 
analyses (Fig. 1). In a further three subjects, the terminal 
phases of celecoxib could not be adequately estimated fol-
lowing administration of CTC in the fasting state. Therefore, 
celecoxib AUC ∞ and T½el were not calculated for these sub-
jects and only 30 subjects were included in the statistical 
analysis of these parameters for celecoxib (Fig. 1). A further 
subject had a measurable pre-dose O-desmethyltramadol 
concentration before the first treatment period, despite con-
firming that he/she had abided by protocol instructions on 
study drug intake. However, the pre-dose O-desmethyltra-
madol concentration was less than 5% of the Cmax value in 
the first treatment period for this subject and was therefore 
considered unlikely to influence bioequivalence assessment. 
This subject was therefore included in the pharmacokinetic 
analyses.
3.2  Pharmacokinetics
Mean tramadol plasma concentration–time profiles were 
similar in fed and fasting conditions (Fig. 2a). Pharmacoki-
netic parameters for tramadol are summarised in Table 2. 
Tmax and T½el parameters were significantly different (p value 
< 0.05) between fed and fasting states. For Cmax, although 
statistically significant differences were found, geometric LS 
mean fed-to-fasting ratios and their 90% CIs were within the 
Table 1  Subject demographics and other characteristics (N = 36)
SD standard deviation
Characteristic Value







Weight, kg; mean (SD) 65.7 (10.9)
Height, cm; mean (SD) 167.3 (10.5)

















































































































Fig. 2  Mean plasma concentration versus time profiles for tramadol (a); O-desmethyltramadol (b); and celecoxib (c) following a single dose of 
CTC administered under fed or fasting conditions (n = 33). Data are means ± standard deviation. CTC Co-Crystal of Tramadol–Celecoxib
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80–125% range, indicating the absence of a food effect for 
this parameter. In the case of AUC values, no statistically 
significant differences were found, and the geometric LS 
mean fed-to-fasting ratios and their 90% CIs were within 
the 80–125% range, indicating the absence of a food effect 
(Table 3).
Mean plasma concentration–time curves for O-desmeth-
yltramadol were also similar in fed and fasting conditions 
(Fig. 2b). O-desmethyltramadol Cmax, Tmax, AUC and T½el 
values are shown in Table 2. There was no statistically sig-
nificant difference in Cmax between fed and fasting condi-
tions. Although O-desmethyltramadol AUC and T½el values 
had a p value < 0.05 between fed and fasting states, the geo-
metric LS mean fed-to-fasting ratios and corresponding 90% 
CIs were between 80 and 125% for Cmax and for AUC values, 
indicating the absence of a food effect for O-desmethyltra-
madol (Table 3).
The pharmacokinetics of celecoxib were subject to a food 
effect (Fig. 2c). All celecoxib pharmacokinetic parameters 
(Table 2) showed a significant difference (p value < 0.05) 
between the fed and fasting states. Tmax was significantly 
delayed under fed versus fasting conditions (median value 
of 3.67 and 1.25 h, respectively). The half-life of celecoxib 
was shorter in the fed state than in the fasting state (8.22 and 
11.30 h). Fed-to-fasting geometric LS mean ratios and cor-
responding 90% CIs for Cmax, [130.91% (116.98–146.49)], 
AUC t [131.71% (124.54–139.30)] and AUC ∞ [129.34% 
(121.78–137.38)] were outside the 80 and 125% range for 
comparative bioavailability, indicating a food effect on 
celecoxib pharmacokinetics (Table 3).
3.3  Safety
There were no serious AEs or deaths and no subject was 
withdrawn from the study for safety reasons. Twenty-three 
subjects (23/36; 63.9%) experienced a total of 88 AEs. After 
administration of CTC in fed conditions, 17 subjects (17/36; 
47.2%) reported 46 AEs, of which 43 were assessed as pos-
sibly related to study drug. After receipt of CTC in fasting 
conditions, 20 subjects (20/35; 57.1%) reported 42 AEs, of 
Table 2  Summary of PK parameters of tramadol, O-desmethyltramadol and celecoxib following a single dose of CTC administered under fed or 
fasting conditions
ANOVA analysis of variance, AUC t cumulative area under the concentration–time curve from time zero to time of last observed quan-
tifiable plasma concentration, AUC ∞ extrapolated area under the concentration–time curve to infinity, Cmax maximum plasma concentration, 
CTC Co-Crystal of Tramadol-Celecoxib, PK pharmacokinetic, SD standard deviation, T½el elimination half-life, Tmax time to maximum plasma 
concentration
*A statistically significant difference between fed and fasting state [p < 0.05; ANOVA model, with fixed factors of subject effect (nested within 
sequence), the treatment received, the period at which it was received and the sequence in which each treatment was received]
a Data are median (range)





Mean SD Mean SD
Tramadol
 Cmax (ng/mL)* 267.02 57.4 243.61 57.0
 Tmax (h)a,* 3.67 1.75–5.50 (range) 2.67 1.50–6.00 (range)
 AUC t (ng·h/mL) 2719.70 911.1 2773.15 942.9
 AUC ∞ (ng·h/mL) 2801.47 907.7 2857.37 948.6
 T½el (h)* 6.11 1.52 6.58 1.5
O-desmethyltramadol
 Cmax (ng/mL) 56.26 17.6 53.14 319.3
 Tmax (h)a 4.50 2.33–6.00 (range) 4.00 2.33–8.00 (range)
 AUC t (ng·h/mL)* 763.50 210.7 802.77 230.4
 AUC ∞ (ng·h/mL)* 781.47 209.4 825.04 231.8
 T½el (h)* 6.74 1.5 7.38 1.5
Celecoxib
 Cmax (ng/mL)* 525.57 182.4 410.31 171.1
 Tmax (h)a,* 3.67 1.00–6.00 (range) 1.25 0.75–6.00 (range)
 AUC t (ng·h/mL)* 4411.11 2576.1 3450.35 2508.4
 AUC ∞ (ng·h/mL)b,* 4514.43 3002.1 3615.20 2921.1
 T½el (h)b,* 8.22 3.0 11.30 4.4
825Effect of Food on Co-Crystal of Tramadol–Celecoxib Bioavailability
which 40 were assessed as possibly related to study drug. 
Dizziness [reported in 7/36 (19.4%) and 9/35 (25.7%) of 
subjects in fed and fasting states, respectively], somnolence 
[8 (22.2%) and 4 (11.4%)] and nausea [5 (13.9%) and 5 
(14.3%)] were the most commonly reported AEs (Table 4). 
AEs ranged from mild to severe. Four severe AEs were 
recorded after treatment in the fed state [nausea (n = 2) and 
vomiting (n = 2)] and two after treatment in the fasting state 
[dizziness (n = 1) and vomiting (n = 1); Table 4]. Two sub-
jects required rescue medication for headache following the 
first administration of CTC. Two subjects had clinically sig-
nificant urinalysis laboratory values after the study (one sub-
ject was positive for white blood cells and one for red blood 
cells). Both were lost to follow-up before end-of-study. No 
clinically significant effects on vital signs, ECGs or physical 
examination were noted during the study.
4  Discussion
In this randomised crossover study of healthy male and 
female subjects, the bioavailability of tramadol after a sin-
gle dose of CTC, as determined by bioequivalence analy-
ses, was unaffected by food, whereas that of celecoxib was 
increased after consumption of a high-fat meal. Absorption 
of celecoxib was also slowed in the fed state compared with 
the fasting state. The single-dose safety profile of CTC was 
similar following administration in the fed or fasting state 
and CTC was well tolerated under both conditions.
The primary results from the current study, namely that 
food had no effect on tramadol bioavailability but increased 
celecoxib bioavailability, are consistent with those observed 
when the standard drug formulations of tramadol and 
celecoxib are administered individually. Food intake does 
not affect the bioavailability of standard-formulation trama-
dol [13]. However, for standard-formulation celecoxib, 
high-fat meals are known to increase celecoxib Cmax by 
approximately 40–60% and AUC by 10–20%, and delay 
absorption by approximately 1–2 h, compared with fasting 
conditions [14, 15]. In vitro studies have suggested that this 
effect of food on celecoxib bioavailability may be linked to 
an increase in bile secretion [18].
In line with regulatory requirements [16, 17], this Phase 
1 food effect study was conducted using a randomized, two-
period, two-sequence, single-dose, crossover design, in 
healthy volunteers. While such a design has some inherent 
limitations, we do not believe that these negatively impact 
on data interpretation. For example, the European Medicines 
Table 3  Comparative bioavailability of tramadol, O-desmethyltrama-
dol and celecoxib following a single dose of CTC administered under 
fed or fasting conditions
AUC t cumulative area under the concentration–time curve from time 
zero to time of last observed quantifiable plasma concentration, AUC 
∞ extrapolated area under the concentration–time curve to infin-
ity, CI confidence interval, Cmax maximum plasma concentration, 
CTC Co-Crystal of Tramadol-Celecoxib, LS least-squares
a n = 30 for celecoxib AUC ∞
Parameter Geometric LS 
means (n = 33)
Ratio (%) 90% CIs
Fed Fasting
Tramadol
 Cmax (ng/mL) 261.05 236.40 110.43 105.34–115.76
 AUC t (ng·h/mL) 2570.81 2616.33 98.26 94.48–102.20
 AUC ∞ (ng·h/mL) 2660.36 2704.35 98.37 94.85–102.02
O-desmethyltramadol
 Cmax (ng/mL) 53.27 49.66 107.29 101.60–113.30
 AUC t (ng·h/mL) 733.18 768.41 95.41 92.40–98.53
 AUC ∞ (ng·h/mL) 752.37 791.27 95.08 92.08–98.19
Celecoxib
 Cmax (ng/mL) 499.47 381.54 130.91 116.98–146.49
 AUC t (ng·h/mL) 4037.17 3065.13 131.71 124.54–139.30
 AUC ∞ (ng·h/mL)a 4087.73 3160.35 129.34 121.78–137.38
Table 4  Summary of adverse events
Each subject was counted only once per drug administration within 
each system organ class and MedDRA preferred AE term






Subjects with at least one AE, n (%) 17 (47.2) 20 (57.1)
Number of AEs 46 42
Most commonly reported AEs occurring in at least two subjects 









General disorders and administration site conditions
 Fatigue 0/0 2/2
 Pallor 1/1 1/1
Injury, poisoning and procedural complications
 Vessel puncture site reaction 2/2 0/0
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Agency recommends single-dose studies for their superior 
sensitivity in detecting differences in Cmax when compared 
to the same design using multiple doses. In addition, regula-
tory authorities suggest that bioequivalence studies be con-
ducted in healthy volunteers where possible, and that this 
permits extrapolation to other populations [16, 17].
The data reported herein are supported by findings from 
other CTC clinical trials. The fasting pharmacokinetic data 
obtained in the present study are similar to those collected 
in earlier Phase 1 studies of CTC, in which dosing was car-
ried out under fasting conditions [11, 12]. In the present 
study, median Tmax values of celecoxib and tramadol after 
CTC dosing under fasting conditions were 1.25 and 2.67 h, 
respectively. In an earlier single-dose Phase 1 CTC study, 
corresponding median Tmax values after CTC dosing under 
fasting conditions were 1.50 and 2.67 h for celecoxib and 
tramadol, respectively. These values were slightly higher in 
the case of tramadol, and lower in the case of celecoxib, than 
those obtained after administration of reference products 
alone or in free combination [11]. In the present study, mean 
fasting Cmax values after CTC administration were 410 and 
244 ng/mL, for celecoxib and tramadol, respectively. This 
compares with values of 313 and 263 ng/mL in the earlier 
single-dose Phase 1 study. Similar results were also observed 
for AUC values [11]. Differences in values between the two 
studies are within the range of inter-subject variability. The 
modified pharmacokinetic profile of tramadol and celecoxib 
after CTC administration, seen in this earlier study, is con-
sistent with the fasting pharmacokinetic data reported here.
In the present study, the single-dose safety profile of CTC 
was similar in both fed and fasting conditions. CTC was well 
tolerated and there were no clinically significant effects of 
treatment on vital signs, ECGs or physical examination, and 
no serious AEs, safety-related withdrawals or deaths. The 
total number of AEs and the number of subjects who expe-
rienced at least one AE were similar under both conditions. 
The most frequently observed AEs were consistent with 
commonly reported AEs from previous Phase 1 and Phase 
2 studies of CTC [10–12] and for standard drug formulations 
of tramadol and celecoxib [13, 14].
5  Conclusion
In conclusion, food increased the bioavailability of celecoxib 
from CTC in healthy subjects but had no effect on the bio-
availability of tramadol. These findings are in line with those 
reported for the standard drug formulations of the individual 
reference products [13, 14]. The food effect on the bioavail-
ability of celecoxib after CTC administration was not suffi-
cient to indicate that any dose adjustment would be required. 
In line with dosing recommendations for other tramadol 
and celecoxib preparations [14, 19], it is anticipated that 
no specific dosing recommendations will be necessary in 
relation to meal times. Following demonstration of efficacy 
in a Phase 2 study of acute pain following an oral surgical 
procedure [10], CTC is now under evaluation in Phase 3 
studies of bunionectomy with osteotomy [20], acute pain 
following an oral surgical procedure [21] and hysterectomy-
related pain [22].
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